Antiphospholipid Syndrome-Not a Noninflammatory Disease

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 6, 2015, Pages 607-614

  De Groot, Philip G ^a   Urbanus, Rolf T ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

antiphospholipid syndrome; complement; infection; inflammation; 2< inf> glycoprotein I

Indexed keywords

BETA2 GLYCOPROTEIN 1; PHOSPHOLIPID ANTIBODY; AUTACOID; AUTOANTIBODY; AUTOANTIGEN;

ANTIBODY PRODUCTION; ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; ARTICLE; CLINICAL FEATURE; COMPLEMENT SYSTEM; ENDOTHELIAL DYSFUNCTION; HUMAN; INFECTION; INFLAMMATION; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; ABORTION, HABITUAL; BLOOD; COMPLEMENT ACTIVATION; COMPLICATION; FEMALE; IMMUNOLOGY; LEUKOCYTE; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE MICROPARTICLE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOPHILIA; VASCULAR ENDOTHELIUM;

ABORTION, HABITUAL; ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; AUTOANTIBODIES; AUTOANTIGENS; BETA 2-GLYCOPROTEIN I; CELL-DERIVED MICROPARTICLES; COMPLEMENT ACTIVATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNITY, INNATE; INFECTION; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTES; LYMPHOCYTE ACTIVATION; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOPHILIA;

EID: 84941756377     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0035-1556725     Document Type: Article

References (78)

1. Miyakis S., Lockshin M. D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost: 2006; 4 2 295 306
2. Galli M., Comfurius P., Maassen C., et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet: 1990; 335 8705 1544 1547
3. Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet (London, England): 1990; 366 117 118
4. McNeil H. P., Simpson R. J., Chesterman C. N., Krilis S. A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A: 1990; 87 11 4120 4124
5. Cervera R., Piette J. C., Font J., et al. Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum: 2002; 46 4 1019 1027
6. Golan T. D. Lupus vasculitis: differential diagnosis with antiphospholipid syndrome. Curr Rheumatol Rep: 2002; 4 1 18 24
7. Lie J. T. Vasculopathy of the antiphospholipid syndromes revisited: thrombosis is the culprit and vasculitis the consort. Lupus: 1996; 5 5 368 371
8. Wilson W. A., Gharavi A. E., Koike T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum: 1999; 42 7 1309 1311
9. de Groot P. G., Meijers J. C. β(2)-Glycoprotein I: evolution, structure and function. J Thromb Haemost: 2011; 9 7 1275 1284
10. Horbach D. A., van Oort E., Lisman T., Meijers J. C., Derksen R. H., de Groot P. G. Beta2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb Haemost: 1999; 81 1 87 95
11. Sendoel A., Hengartner M. O. Apoptotic cell death under hypoxia. Physiology (Bethesda): 2014; 29 3 168 176
12. Cheng H. M. Physiologic apoptosis, beta 2-glycoprotein I, and antiphospholipid autoantibodies. Am J Obstet Gynecol: 1996; 175 5 1393
13. Balasubramanian K., Chandra J., Schroit A. J. Immune clearance of phosphatidylserine-expressing cells by phagocytes. The role of beta2-glycoprotein I in macrophage recognition. J Biol Chem: 1997; 272 49 31113 31117
14. Balasubramanian K., Schroit A. J. Characterization of phosphatidylserine-dependent beta2-glycoprotein I macrophage interactions. Implications for apoptotic cell clearance by phagocytes. J Biol Chem: 1998; 273 44 29272 29277
15. Agar C., de Groot P. G., Mörgelin M., et al. β2-glycoprotein I: a novel component of innate immunity. Blood: 2011; 117 25 6939 6947
16. Agar C., van Os G. M., Mörgelin M., et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood: 2010; 116 8 1336 1343
17. Du V. X., van Os G., Kremer Hovinga J. A., et al. Indications for a protective function of beta2-glycoprotein I in thrombotic thrombocytopenic purpura. Br J Haematol: 2012; 159 1 94 103
18. Lin F., Murphy R., White B., et al. Circulating levels of beta2-glycoprotein I in thrombotic disorders and in inflammation. Lupus: 2006; 15 2 87 93
19. Poon I. K., Patel K. K., Davis D. S., Parish C. R., Hulett M. D. Histidine-rich glycoprotein: the Swiss Army knife of mammalian plasma. Blood: 2011; 117 7 2093 2101
20. Yeaman M. R., Bayer A. S. Antimicrobial peptides versus invasive infections. Curr Top Microbiol Immunol: 2006; 306 111 152
21. Nilsson M., Wasylik S., Mörgelin M., et al. The antibacterial activity of peptides derived from human beta-2 glycoprotein I is inhibited by protein H and M1 protein from Streptococcus pyogenes. Mol Microbiol: 2008; 67 3 482 492
22. Raschi E., Chighizola C. B., Grossi C., et al. β2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis. J Autoimmun: 2014; 55 42 50
23. Fleming S. D., Pope M. R., Hoffman S. M., et al. Domain V peptides inhibit beta2-glycoprotein I-mediated mesenteric ischemia/reperfusion-induced tissue damage and inflammation. J Immunol: 2010; 185 10 6168 6178
24. Pope M. R., Bukovnik U., Tomich J. M., Fleming S. D. Small β2-glycoprotein I peptides protect from intestinal ischemia reperfusion injury. J Immunol: 2012; 189 10 5047 5056
25. Tomasi M., Hiromasa Y., Pope M. R., Gudlur S., Tomich J. M., Fleming S. D. Human β2-glycoprotein I attenuates mouse intestinal ischemia/reperfusion induced injury and inflammation. Mol Immunol: 2012; 52 3-4 207 216
26. Forastiero R., Martinuzzo M., de Larrañaga G., Vega-Ostertag M., Pierangeli S. Anti-β2glycoprotein I antibodies from leprosy patients do not show thrombogenic effects in an in vivo animal model. J Thromb Haemost: 2011; 9 4 859 861
27. de Laat B., Derksen R. H., Urbanus R. T., de Groot P. G. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood: 2005; 105 4 1540 1545
28. Male C., Foulon D., Hoogendoorn H., et al. Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood: 2005; 106 13 4152 4158
29. Pengo V., Biasiolo A., Fior M. G. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when beta 2-glycoprotein I is bound to a suitable surface. Thromb Haemost: 1995; 73 1 29 34
30. Hattori N., Kuwana M., Kaburaki J., Mimori T., Ikeda Y., Kawakami Y. T cells that are autoreactive to beta2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis Rheum: 2000; 43 1 65 75
31. de Laat B., van Berkel M., Urbanus R. T., et al. Immune responses against domain I of β(2)-glycoprotein I are driven by conformational changes: domain I of β(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum: 2011; 63 12 3960 3968
32. Sène D., Piette J. C., Cacoub P. Antiphospholipid antibodies, antiphospholipid syndrome and infections. Autoimmun Rev: 2008; 7 4 272 277
33. Rose N. R. Autoimmunity, infection and adjuvants. Lupus: 2010; 19 4 354 358
34. van Os G. M., Meijers J. C., Agar Ç., et al. Induction of anti-β2 -glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes. J Thromb Haemost: 2011; 9 12 2447 2456
35. Levine J. S., Subang R., Nasr S. H., et al. Immunization with an apoptotic cell-binding protein recapitulates the nephritis and sequential autoantibody emergence of systemic lupus erythematosus. J Immunol: 2006; 177 9 6504 6516
36. Andreoli L., Fredi M., Nalli C., Franceschini F., Meroni P. L., Tincani A. Antiphospholipid antibodies mediate autoimmunity against dying cells. Autoimmunity: 2013; 46 5 302 306
37. Dlott J. S., Roubey R. A. Drug-induced lupus anticoagulants and antiphospholipid antibodies. Curr Rheumatol Rep: 2012; 14 1 71 78
38. Merrill J. T., Shen C., Gugnani M., Lahita R. G., Mongey A. B. High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol: 1997; 24 6 1083 1088
39. Passam F. H., Giannakopoulos B., Mirarabshahi P., Krilis S. A. Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative post-translational modification of beta 2 glycoprotein I. J Thromb Haemost: 2011; 9 01 275 282
40. Albert L. J., Inman R. D. Molecular mimicry and autoimmunity. N Engl J Med: 1999; 341 27 2068 2074
41. Lockshin M. D., Kim M., Laskin C. A., et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum: 2012; 64 7 2311 2318
42. Ruffatti A., Del Ross T., Ciprian M., et al. Antiphospholipid Syndrome Study Group of Italian Society of Rheumatology. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis: 2011; 70 6 1083 1086
43. Pengo V., Ruffatti A., Legnani C., et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood: 2011; 118 17 4714 4718
44. Fischetti F., Durigutto P., Pellis V., et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood: 2005; 106 7 2340 2346
45. Cervera R., Bucciarelli S., Plasín M. A., et al. Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum On Antiphospholipid Antibodies). Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the CAPS Registry J Autoimmun: 2009; 32 3-4 240 245
46. Rand J. H., Wu X. X., Guller S., Scher J., Andree H. A., Lockwood C. J. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi. Am J Obstet Gynecol: 1997; 177 4 918 923
47. Krikun G., Lockwood C. J., Wu X. X., et al. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation. Placenta: 1994; 15 6 601 612
48. Weinbaum S., Tarbell J. M., Damiano E. R. The structure and function of the endothelial glycocalyx layer. Annu Rev Biomed Eng: 2007; 9 121 167
49. Allen K. L., Hamik A., Jain M. K., McCrae K. R. Endothelial cell activation by antiphospholipid antibodies is modulated by Kruppel-like transcription factors. Blood: 2011; 117 23 6383 6391
50. Dunoyer-Geindre S., de Moerloose P., Galve-de Rochemonteix B., Reber G., Kruithof E. K. NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies. Thromb Haemost: 2002; 88 5 851 857
51. Dekker R. J., van Soest S., Fontijn R. D., et al. Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Krüppel-like factor (KLF2). Blood: 2002; 100 5 1689 1698
52. Ramesh S., Morrell C. N., Tarango C., et al. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. J Clin Invest: 2011; 121 1 120 131
53. Romay-Penabad Z., Aguilar-Valenzuela R., Urbanus R. T., et al. Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood: 2011; 117 4 1408 1414
54. Pierangeli S. S., Espinola R. G., Liu X., Harris E. N. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res: 2001; 88 2 245 250
55. Dignat-George F., Camoin-Jau L., Sabatier F., et al. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost: 2004; 91 4 667 673
56. Proulle V., Furie R. A., Merrill-Skoloff G., Furie B. C., Furie B. Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. Blood: 2014; 124 4 611 622
57. Kornberg A., Blank M., Kaufman S., Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol: 1994; 153 3 1328 1332
58. Redecha P., Tilley R., Tencati M., et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood: 2007; 110 7 2423 2431
59. Xie H., Zhou H., Wang H., et al. Anti-β(2)GPI/β(2)GPI induced TF and TNF-α expression in monocytes involving both TLR4/MyD88 and TLR4/TRIF signaling pathways. Mol Immunol: 2013; 53 3 246 254
60. Erkan D., Willis R., Murthy V. L., et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis: 2014; 73 6 1176 1180
61. Berman J., Girardi G., Salmon J. E. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol: 2005; 174 1 485 490
62. Redecha P., Franzke C. W., Ruf W., Mackman N., Girardi G. Neutrophil activation by the tissue factor/factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest: 2008; 118 10 3453 3461
63. Gladigau G., Haselmayer P., Scharrer I., et al. A role for Toll-like receptor mediated signals in neutrophils in the pathogenesis of the anti-phospholipid syndrome. PLoS ONE: 2012; 7 7 e42176
64. Girardi G., Berman J., Redecha P., et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest: 2003; 112 11 1644 1654
65. Sorice M., Longo A., Capozzi A., et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum: 2007; 56 8 2687 2697
66. Deora A. B., Kreitzer G., Jacovina A. T., Hajjar K. A. An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface. J Biol Chem: 2004; 279 42 43411 43418
67. Hazeltine M., Rauch J., Danoff D., Esdaile J. M., Tannenbaum H. Antiphospholipid antibodies in systemic lupus erythematosus: evidence of an association with positive Coombs' and hypocomplementemia. J Rheumatol: 1988; 15 1 80 86
68. Walport M. J. Complement. First of two parts. N Engl J Med: 2001; 344 14 1058 1066
69. Pierangeli S. S., Girardi G., Vega-Ostertag M., Liu X., Espinola R. G., Salmon J. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum: 2005; 52 7 2120 2124
70. Carrera-Marín A., Romay-Penabad Z., Papalardo E., et al. C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies. Lupus: 2012; 21 14 1497 1505
71. Agostinis C., Durigutto P., Sblattero D., et al. A non complement-fixing antibody to beta2 glycoprotein I as a novel therapy to control abortions and thrombosis in antiphospholipid syndrome. Blood: 2014; 123 3478 3487
72. Holers V. M., Girardi G., Mo L., et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med: 2002; 195 2 211 220
73. Girardi G., Redecha P., Salmon J. E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med: 2004; 10 11 1222 1226
74. Shapira I., Andrade D., Allen S. L., Salmon J. E. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum: 2012; 64 8 2719 2723
75. Thurman J. M., Kraus D. M., Girardi G., et al. A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice. Mol Immunol: 2005; 42 1 87 97
76. Wirthmueller U., Dewald B., Thelen M., et al. Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils. J Immunol: 1997; 158 9 4444 4451
77. Schwaeble W. J., Reid K. B. Does properdin crosslink the cellular and the humoral immune response? Immunol Today: 1999; 20 1 17 21
78. Jankowski M., Vreys I., Wittevrongel C., et al. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood: 2003; 101 1 157 162